Pfizer and Thermo Fisher Scientific partner to bring accessible NGS-based testing to international markets
The collaboration between the pharmaceutical giant and scientific technology provider will aim to bring rapid and localised services to areas around the globe that lack affordable advanced genomic testing for breast and lung cancer.
Pfizer and Thermo Fisher Scientific have entered into a partnership agreement for the expansion of access to next-generation sequencing (NGS)-based testing for patients with lung and breast cancer. With local access set to increase in 30 countries across Latin America, Africa, the Middle East, and Asia, the collaboration hopes to bring advanced genomic testing to previously inaccessible regions of the globe.
As the leading cause of death around the world and nearly 10 million deaths attributed to the disease in 2020, breast and lung cancer are the leading types of diagnosed cancer. The global burden, both economic and social, is expected to reach 27.5 million new cases in 2040 and 16.3 million deaths. While gene testing has historically been used to match patients with the appropriate targeted therapies, the standard single-gene biomarker testing can be time-consuming, with sequential tests and enough tissue and organic material to run each test. NGS technology provides healthcare professionals and clinical trial teams with rapid genomic information to make informed precision oncology treatment decisions. Some decisions can affect the survival rate and time-to-next treatment, so it is crucial to identify actionable treatments from rapid molecular testing to make informed treatment decisions.
Gianluca Pettiti, Executive VP at Thermo Fisher Scientific, commented: “Anyone facing a cancer diagnosis should have access to cutting-edge testing that can match them with an appropriate, optimised treatment plan and better inform their care. Today, we aim to bring rapid NGS testing to an increased number of decentralised labs, closer to where patients are treated. We are moving one step closer to delivering precision insights to underserved patients so they can receive a more tailored path for their care no matter where they are in the world.”
The agreement will see Thermo Fisher identifying local labs that can house the organisation’s NGS technology with the necessary infrastructure, skilled staff and staff training, and quality control methods that meet industry standards for NGS testing for breast and lung cancer. Pfizer, under the collaboration, will be responsible for exploring different avenues of affordable patient access to NGS testing for breast and lung cancer. Promotion of healthcare provider awareness regarding advanced testing and the need for such tests will be a main priority for Pfizer, and the partnership will continuously evaluate new opportunities to expand both geographically and to testing for other types of cancers.
Pfizer’s Global President of Emerging Markets Nick Lagunowich stated: “The more we understand the complex science behind cancer, the better we can treat it. Our experience has taught us that cancer cannot always be treated with a broad brush and often requires an individualised approach based on precise disease characteristics. In many parts of the world, access to next-generation sequencing may be limited or unaffordable for cancer patients. This program aims to improve their treatment journey and help increase their chances for improved outcomes.”
Source: Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets [Accessed May 10, 2023] https://www.businesswire.com/news/home/20230509005516/en/Thermo-Fisher-Scientific-Pfizer-Partner-to-Expand-Localized-Access-to-Next-Generation-Sequencing-Based-Testing-for-Cancer-Patients-in-International-Markets%C2%A0
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance